HLB LifeScience Co., Ltd.

Elevar Therapeutics, a US subsidiary of South Korea’s HLB LifeScience, and China’s Jiangsu Hengrui Pharmaceuticals on 21 March received a complete response letter from the US Food and Drug Administrat

A third-party vendor undermined Applied Therapeutics ’ bid to bring the first drug for the rare genetic metabolic disease galactosemia to market by deleting electronic clinical outcome assessment dat

Disappointing news appeared to overflow in the South Korean biotech sector in the second quarter amid multiple returned assets from global partners, a lack of major new out-licensing deals, as well as

HLB LifeScience Co., Ltd. and Jiangsu Hengrui Medicine Co., Ltd. ’s combination therapy for liver cancer has hit a stumbling block in the form of a US complete response letter (CRL), mainly related